Description: Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.
Home Page: www.anebulo.com
ANEB Technical Analysis
1415 Ranch Road 620 South
Lakeway,
TX
78734
United States
Phone:
512-598-0931
Officers
| Name | Title |
|---|---|
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman |
| Mr. Simon J. Allen B.Sc., M.B.A., MBA | CEO & Director |
| Mr. Rex Merchant CFA | CFO & Sec. |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |
| Mr. Scott L. Anderson | Head of Investor Relations & Public Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.514 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-05-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |